Investment supports next phase of growth, platform innovation, and international expansion.
LONDON, UK – Tuesday 24th February 2026 – Access Infinity, a global market access partner combining innovative technology and expert consulting solutions, today announced it has secured an investment from CBPE Capital (“CBPE”) to accelerate its next phase of growth.
CBPE has a strong track record of supporting ambitious, high-growth businesses in the healthcare and technology sectors. Its investment in Access Infinity reflects CBPE’s confidence in the company’s leadership team, differentiated platform and long-term growth potential.
The partnership will enable Access Infinity to further enhance its technology platform and accelerate international expansion. It will also support continued investment in talent, innovation, and client services, building on a customer base that already includes 22 of the world’s top 25 pharmaceutical companies.
Founded in 2014, Access Infinity has established itself as a trusted partner for life sciences companies worldwide, providing a suite of software and consulting services that support clients throughout the drug development lifecycle. The company’s innovative software solutions (comprising Access HubTM, Evidence HubTM and NuroTM) and expert consulting team help pharma clients navigate complex global market access challenges, optimise pricing strategies, and deliver value to patients across diverse healthcare systems.
Shrinivas Rao Mukku and Ahmed Edathodu, Founding Directors of Access Infinity, commented: “We are delighted to partner with CBPE for the next stage of our journey. Their experience and support will be invaluable as we continue to grow our business, invest in our people, and deliver exceptional value to our clients.”
Naveen Passi, Partner at CBPE, added: “We have been hugely impressed by Access Infinity’s expertise, innovation, and client-centric approach. We are excited to be working closely with the team to help realise their exciting plans for growth and continued leadership in the market access space.”
Terms of the transaction were not disclosed.
For more information about Access Infinity go to accessinfinity.com.
Further information about CBPE is available here: cbpe.com.
About Access Infinity
Founded in 2014, Access Infinity helps pharmaceutical companies launch and price their products more effectively by combining deep strategic consulting expertise with digital platforms purpose-built for market access and HEOR teams. The company’s experienced consultants work closely with global through to local teams to shape launch strategies, optimise pricing and access, and navigate complex policy landscapes.
Access Infinity’s core digital solutions – Access Hub, Evidence Hub and Nuro – streamline everything from launch tracking and evidence planning to pricing strategy, enabling faster, smarter, and more coordinated decision-making across the product lifecycle. With offices in London, Manchester and Hyderabad, Access Infinity’s clients include many of the pharmaceutical industry’s most influential companies including AstraZeneca, GSK, J&J, MSD, and Pfizer.
For media enquiries, please contact:
Email: louise@accessinfinity.com
Tel: +44 (0)7548478748
